Results 231 to 240 of about 943,185 (296)

Interstitial Lung Diseases and Lung Cancer: A Review on Similarities, Common Pathogenesis and Therapeutic Approach. [PDF]

J Pers Med
Castelli G, Cocconcelli E, Grimaudo G, Di Leo I, Bellani S, Fiorentù G, Giulianelli G, Bernardinello N, Balestro E, Spagnolo P.   +9 more
europepmc   +1 more source

Imaging of Lipid Droplets in Living Cells and Mice with Metabolic Dysfunction‐Associated Steatotic Liver Disease via a Galactose‐Modified Supramolecular Near‐Infrared Fluorescent Glycoprobe

Advanced Functional Materials, EarlyView.
A galactose‐modified supramolecular near‐infrared (NIR) glycoprobe, TCF‐FBN@Gal‐BSA, enables targeted delivery to the liver through the asialoglycoprotein receptor (ASGPR) and facilitates liver‐targeting fluorescence visualization of lipid droplets (LDs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) mice.
Han‐Min Wang, Lei Dong, Qiu‐Lian Hao, Lu‐Lu Sun, Xin‐Rong Li, Yu‐Wei Yuan, Ming‐Ye Tang, Jin Gong, Yi Zang, Jia Li, Tony D. James, Xiao‐Peng He, Hai‐Hao Han   +12 more
wiley   +1 more source

Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases. [PDF]

Diagnostics (Basel)
Trushenko NV, Suvorova OA, Schmidt AE, Chikina SY, Levina IA, Lavginova BB, Avdeev SN.   +6 more
europepmc   +1 more source

HODGKIN's DISEASE OF THE LUNG

, 1965
David T. Monahan
openalex   +1 more source

Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy

Advanced Functional Materials, EarlyView.
This review highlights recent advances in engineering artificial antigen‐presenting cells (aAPCs) as alternatives to dendritic cells for T cell expansion. Key design principles inspired by the immunological synapse are discussed, with emphasis on strategies for polyclonal and antigen‐specific T cell expansion.
Nguyen Thi Nguyen, Yu Seok Youn
wiley   +1 more source

Serratia sp. traits distinguish the lung microbiome of patients with tuberculosis and non-tuberculous mycobacterial lung diseases. [PDF]

PLoS One
Belheouane M, Kalsdorf B, Niemann S, Gaede KI, Lange C, Heyckendorf J, Merker M.   +6 more
europepmc   +1 more source

Intraoral Drug Delivery: Bridging the Gap Between Academic Research and Industrial Innovations

Advanced Functional Materials, EarlyView.
Intraoral drug delivery offers a promising route for systemic and localized therapies, yet challenges such as enzymatic degradation, limited permeability, and microbial interactions hinder efficacy. This figure highlights innovative strategies—mucoadhesive materials, enzyme inhibitors, and permeation enhancers—to overcome these barriers.
Soheil Haddadzadegan, Simona Summonte, Fabrizio Ricci, Matthias Sandmeier, Andreas Bernkop‐Schnürch   +4 more
wiley   +1 more source

Pulmonary hypertension associated with lung diseases. [PDF]

Eur Respir J
Shlobin OA, Adir Y, Barbera JA, Cottin V, Harari S, Jutant EM, Pepke-Zaba J, Ghofrani HA, Channick R.   +8 more
europepmc   +1 more source

Flow‐Induced Vascular Remodeling on‐Chip: Implications for Anti‐VEGF Therapy

Advanced Functional Materials, EarlyView.
Flow‐induced vascular remodeling plays a critical role in network stabilization and function. Using a vasculature‐on‐chip system, this study reveals how physiological VEGF levels and flow affect vascular remodeling and provides insights into tumor vessel normalization.
Fatemeh Mirzapour‐Shafiyi, Elias Huber, Leonie Karr, Johnny Tong, Andreas Richard Bausch, Friedrich Christian Simmel, Karen Alim   +6 more
wiley   +1 more source

cGAS-STING targeting offers therapy choice in lung diseases. [PDF]

Biol Direct
Wang Y, Zhang X, Wang W, Zhang Y, Fleishman JS, Wang H.   +5 more
europepmc   +1 more source